In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Humacyte Inc (NASDAQ: HUMA) was $2.49 for the day, up 11.66% from the previous closing price of $2.23. In other words, the price has increased by $11.66 from its previous closing price. On the day, 6.53 million shares were traded. HUMA stock price reached its highest trading level at $2.51 during the session, while it also had its lowest trading level at $2.0.
Ratios:
Our analysis of HUMA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.68. In the meantime, Its Debt-to-Equity ratio is 2.28 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 20, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $12 to $15.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.H.C. Wainwright initiated its Buy rating on December 11, 2023, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 14 ’25 when Scheessele William John bought 6,493 shares for $1.54 per share. The transaction valued at 9,999 led to the insider holds 22,018 shares of the business.
Sander Dale A. bought 20,000 shares of HUMA for $30,600 on Apr 10 ’25. The CFO and Chief Corp. Deve. Off. now owns 40,600 shares after completing the transaction at $1.53 per share. On Apr 10 ’25, another insider, Parikh Shamik J, who serves as the Chief Medical Officer of the company, bought 7,500 shares for $1.55 each. As a result, the insider paid 11,625 and bolstered with 7,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 386246336 and an Enterprise Value of 405910848. For the stock, the TTM Price-to-Sale (P/S) ratio is 742.77 while its Price-to-Book (P/B) ratio in mrq is 10.72. Its current Enterprise Value per Revenue stands at 785.127 whereas that against EBITDA is -3.912.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.88, which has changed by -0.6706349 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 31.30%, while the 200-Day Moving Average is calculated to be -41.37%.
Shares Statistics:
HUMA traded an average of 4.31M shares per day over the past three months and 5761860 shares per day over the past ten days. A total of 155.12M shares are outstanding, with a floating share count of 125.75M. Insiders hold about 18.94% of the company’s shares, while institutions hold 39.72% stake in the company. Shares short for HUMA as of 1745971200 were 25152561 with a Short Ratio of 5.84, compared to 1743379200 on 27135345. Therefore, it implies a Short% of Shares Outstanding of 25152561 and a Short% of Float of 18.67.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
